Fig 1: Representative microphotographs of DLL4 immunohistochemistry. (A) low DLL4 expression, intestinal-type; (B) high DLL4 expression, intestinal-type; (C) low DLL4 expression, diffuse-type; and (D) high DLL4 expression, diffuse-type gastric adenocarcinomas
Fig 2: Representative images of expression of anti-DLL4 and anti-VEGF antibodies in gallbladder cancer of each group, according to the Hscore calculated via Aperio ImageScope software. (A) High membranous expression of anti-DLL4 antibody (H-score 208.43). (B) Low membranous expression of anti-DLL4 antibody (H-score 40.28). (C) High cytoplasmic expression of anti-VEGF antibody (H-score 214.01). (D) Low cytoplasmic expression of anti-VEGF antibody (H-score 34.36). DLL4, delta-like ligand 4; VEGF, vascular endothelial growth factor.
Fig 3: Images of hematoxylin and eosin stain (A) and expression of anti-DLL4 (B), anti-VEGF (C), and anti-HIF2a (D) antibodies in the corresponding area, showing tumor and surrounding soft tissue, including vessel, muscle, and nerve. Expression of anti-HIF2a antibody shows extensive background stain compared to other markers, which led to manual scoring of H-score. Digital image analysis would mistake the background staining and overestimate the H-score of such cases. DLL4, delta-like ligand 4; VEGF, vascular endothelial growth factor; HIF2a, hypoxia-inducible factor-2a.
Fig 4: The correlation matrix visualizing the correlation between the expression levels of DLL4, VEGF, and HIF2a (A). The Spearman correlation coefficients are recorded in the center of each box. The scatter plot showing the positive correlation between VEGF and HIF2a (B). DLL4, delta-like ligand 4; VEGF, vascular endothelial growth factor; HIF2a, hypoxia-inducible factor-2a.
Supplier Page from MilliporeSigma for Anti-DLL4 antibody produced in rabbit